Heart FailureCARDIO-REANCT07385404
Factors Contributing to Readmission of Heart Failure Patients to Emergency Departments and Prospects for Improvement
An observational study of Heart Failure and Readmissions, run by Centre Hospitalier Régional Metz-Thionville at 1 site in France.
Trial summary
Heart failure (HF) represents a major public health challenge due to its increasing prevalence and significant impact on healthcare systems. The burden of frequent readmissions leads to increased healthcare costs, deterioration in the quality of care, and reduced availability of hospital resources for new patients. Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- Heart Failure, Readmissions
- How many people
- 58 participants
- Where
- 1 siteFrance
- Study dates
- 1 Jan 2025to 30 Jun 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients hospitalized for acute heart failure over a period of 6 months.
Who may be able to join
- Patients aged 18 years or older, admitted to the emergency department for confirmed acute heart failure. Hospitalization following admission to the emergency department, with at least one documented post-hospitalization follow-up visit.
Who cannot join
- Patients under the age of 18 with a primary diagnosis unrelated to heart failure after analysis of their medical records. Patients in palliative care receiving only comfort treatment. No documented post-hospitalization follow-up. Patients who object to the use of their medical data for research purposes.
Trial locations and contacts
1 site in 1 country.
About this study
Heart failure (HF) represents a major public health challenge due to its increasing prevalence and significant impact on healthcare systems.
The burden of frequent readmissions leads to increased healthcare costs, deterioration in the quality of care, and reduced availability of hospital resources for new patients. It is therefore essential to optimize the management of patients with heart failure from their first visit to the emergency department in order to improve their prognosis and reduce the risk of rehospitalization.
In this context, this study aims to identify the key factors associated with early readmissions (< 30 days) and to propose strategies to improve patient management and follow-up after discharge from hospital.
- Conditions
- Heart Failure, Readmissions
- Medical subject headings
- Heart Failure
What is being measured
The primary outcome is the main question the study is designed to answer.
Key factors determining the rehospitalization
Key factors determining the rehospitalization of patients with heart failure
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Feb 2026
- Study start1 Jan 2025
- Primary completion30 Jun 2025
- Study completion30 Jun 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Heart FailureStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 58 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Régional Metz-Thionville
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Laure ABENSUR VUILLAUME, Principal investigator, CHR Metz Thionville Hopital de Mercy
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07385404
- Sponsor's protocol ID
- 2025-04-Obs-CHRMT
- Acronym
- CARDIO-REA
- Status last verified
- Dec 2025
- First submitted
- 27 Jan 2026
- Last updated
- 4 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Factors Contributing to Readmission of Heart Failure Patients to Emergency Departments and Prospects for Improvement
- ClinicalTrials.gov ID
- NCT07385404
- Acronym / sponsor ID
- CARDIO-REA / 2025-04-Obs-CHRMT
- Conditions
- Heart Failure, Readmissions
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 58 participants (actual)
- Lead sponsor
- Centre Hospitalier Régional Metz-ThionvilleUniversity, hospital or other
- Study start
- 1 Jan 2025 (actual)
- Primary completion
- 30 Jun 2025 (actual)
- Study completion
- 30 Jun 2025 (actual)
- First posted
- 4 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Heart failure (HF) represents a major public health challenge due to its increasing prevalence and significant impact on healthcare systems.
The burden of frequent readmissions leads to increased healthcare costs, deterioration in the quality of care, and reduced availability of hospital resources for new patients. It is therefore essential to optimize the management of patients with heart failure from their first visit to the emergency department in order to improve their prognosis and reduce the risk of rehospitalization.
In this context, this study aims to identify the key factors associated with early readmissions (< 30 days) and to propose strategies to improve patient management and follow-up after discharge from hospital.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients hospitalized for acute heart failure over a period of 6 months.
Key inclusion criteria (1 listed)
- Patients aged 18 years or older, admitted to the emergency department for confirmed acute heart failure. Hospitalization following admission to the emergency department, with at least one documented post-hospitalization follow-up visit.
Key exclusion criteria (1 listed)
- Patients under the age of 18 with a primary diagnosis unrelated to heart failure after analysis of their medical records. Patients in palliative care receiving only comfort treatment. No documented post-hospitalization follow-up. Patients who object to the use of their medical data for research purposes.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Key factors determining the rehospitalization
Time frame: 6 months
Key factors determining the rehospitalization of patients with heart failure
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Feb 2026.
- Individual participant dataSharing planned: No
Related trials for Heart Failure
RecruitingPhase 4
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)
Heart Failure With Reduced Ejection Fraction, Iron Deficiency
Not yet recruitingPhase 2
A Study of Bimagrumab in Participants With HFpEF
Heart Failure, Diastolic, Diastolic Heart Failure
Recruiting
Evaluation of a French Hospital Discharge Therapeutic Education Program by Nurses for Heart Failure Patient (EduSor)
Heart Failure
Active, not recruiting
Assessment of Combined CCM and ICD Device in HFrEF
Heart Failure, Heart Failure With Reduced Ejection Fraction
Not yet recruiting
RELIEVE-HFrEF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure With Reduced EF
Heart Failure and Reduced Ejection Fraction, Heart Failure Chronic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Laure ABENSUR VUILLAUME principal investigator
CHR Metz Thionville Hopital de Mercy
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Heart Failure and Readmissions, run by Centre Hospitalier Régional Metz-Thionville at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Key factors determining the rehospitalization (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Feb 2026.